Xeris Biopharma Tightens FY23 Revenue Guidance From $145M-$165M To $155M-$165M Versus Consensus Of $158.2M; Raises 2023 Cash, Cash Equivalents, And Short-Term Investment Guidance From $55M-$65M to $65M-$70M
Portfolio Pulse from Benzinga Newsdesk
Xeris Biopharma has revised its FY23 revenue guidance from $145M-$165M to $155M-$165M, which is in line with the consensus of $158.2M. The company also increased its 2023 cash, cash equivalents, and short-term investment guidance from $55M-$65M to $65M-$70M.
October 16, 2023 | 11:06 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Xeris Biopharma's updated FY23 revenue and cash guidance aligns with market expectations, which could stabilize the stock price in the short term.
Xeris Biopharma's updated FY23 revenue guidance is in line with the market consensus, which could prevent any drastic changes in the stock price. The increase in cash and short-term investment guidance could also be seen as a positive sign of the company's financial health, potentially attracting investors.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100